



Malmö 30 October 2025

PRESS RELEASE

Aptahem's webinar "Strategic Direction and Planned US Listing" now available

Aptahem hosted a webinar where CEO Mikael Lindstam provided an overview of Aptahem's strategic direction, ongoing preparations for a planned U.S. listing, and recent key regulatory developments.

The webinar is available via the link below:

<https://gumlet.tv/watch/6902846960d267cdc081c34f/>

For further information:

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

Epost: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apt-1, is currently in early clinical phase. Apt-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.